WO2000024893A3 - Methods and compositions for the prevention and treatment of anemia - Google Patents

Methods and compositions for the prevention and treatment of anemia Download PDF

Info

Publication number
WO2000024893A3
WO2000024893A3 PCT/US1999/024435 US9924435W WO0024893A3 WO 2000024893 A3 WO2000024893 A3 WO 2000024893A3 US 9924435 W US9924435 W US 9924435W WO 0024893 A3 WO0024893 A3 WO 0024893A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
analogs
anemia
analog
Prior art date
Application number
PCT/US1999/024435
Other languages
French (fr)
Other versions
WO2000024893A2 (en
Inventor
Joan C Egrie
Steven G Elliott
Jeffrey K Brown
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22651968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000024893(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SI9930955T priority Critical patent/SI1123313T1/en
Priority to CN998146978A priority patent/CN1346369B/en
Priority to CA2345882A priority patent/CA2345882C/en
Priority to KR1020017005047A priority patent/KR20010075661A/en
Priority to JP2000578445A priority patent/JP4809977B2/en
Priority to DE69935345.9T priority patent/DE69935345T3/en
Priority to HU0103920A priority patent/HU228492B1/en
Priority to EP99955046.0A priority patent/EP1123313B2/en
Priority to AU11241/00A priority patent/AU774989B2/en
Priority to DK99955046T priority patent/DK1123313T3/en
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to ES99955046.0T priority patent/ES2283139T5/en
Publication of WO2000024893A2 publication Critical patent/WO2000024893A2/en
Publication of WO2000024893A3 publication Critical patent/WO2000024893A3/en
Priority to IL142334A priority patent/IL142334A/en
Priority to HK02101019.3A priority patent/HK1040944B/en
Priority to IL196645A priority patent/IL196645A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.
PCT/US1999/024435 1998-10-23 1999-10-18 Methods and compositions for the prevention and treatment of anemia WO2000024893A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES99955046.0T ES2283139T5 (en) 1998-10-23 1999-10-18 Methods and compositions for the prevention and treatment of anemia
DK99955046T DK1123313T3 (en) 1998-10-23 1999-10-18 Methods and compositions for the prevention and treatment of anemia
AU11241/00A AU774989B2 (en) 1998-10-23 1999-10-18 Methods and compositions for the prevention and treatment of anemia
KR1020017005047A KR20010075661A (en) 1998-10-23 1999-10-18 Methods and compositions for the prevention and treatment of anemia
CN998146978A CN1346369B (en) 1998-10-23 1999-10-18 Method and compositions for the prevention and treatment of anamia
DE69935345.9T DE69935345T3 (en) 1998-10-23 1999-10-18 METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ANEMIA
HU0103920A HU228492B1 (en) 1998-10-23 1999-10-18 Methods and compositions for the prevention and treatment of anemia
SI9930955T SI1123313T1 (en) 1998-10-23 1999-10-18 Methods and compositions for the prevention and treatment of anemia
CA2345882A CA2345882C (en) 1998-10-23 1999-10-18 Methods and compositions for the prevention and treatment of anemia
JP2000578445A JP4809977B2 (en) 1998-10-23 1999-10-18 Methods and compositions for the prevention and treatment of anemia
EP99955046.0A EP1123313B2 (en) 1998-10-23 1999-10-18 Methods and compositions for the prevention and treatment of anemia
IL142334A IL142334A (en) 1998-10-23 2001-03-29 Methods and compositions for the prevention and treatment of anemia
HK02101019.3A HK1040944B (en) 1998-10-23 2002-02-08 Methods and compositions for the prevention and treatment of anemia
IL196645A IL196645A (en) 1998-10-23 2009-01-21 Use of a hyperglycosylated analog of erythropoietin to prepare a pharmaceutical composition for raising and maintaining hematocrit level

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17829298A 1998-10-23 1998-10-23
US09/178,292 1998-10-23

Publications (2)

Publication Number Publication Date
WO2000024893A2 WO2000024893A2 (en) 2000-05-04
WO2000024893A3 true WO2000024893A3 (en) 2000-09-14

Family

ID=22651968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/024435 WO2000024893A2 (en) 1998-10-23 1999-10-18 Methods and compositions for the prevention and treatment of anemia

Country Status (19)

Country Link
EP (2) EP1123313B2 (en)
JP (2) JP4809977B2 (en)
KR (1) KR20010075661A (en)
CN (2) CN101703760A (en)
AR (1) AR020848A1 (en)
AT (2) ATE355303T1 (en)
AU (1) AU774989B2 (en)
CA (1) CA2345882C (en)
CY (2) CY1107584T1 (en)
DE (2) DE69942680D1 (en)
DK (2) DK1123313T3 (en)
ES (2) ES2283139T5 (en)
HK (1) HK1040944B (en)
HU (1) HU228492B1 (en)
IL (2) IL142334A (en)
PT (2) PT1813624E (en)
SI (2) SI1813624T1 (en)
TW (1) TWI234583B (en)
WO (1) WO2000024893A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7847079B2 (en) 2001-12-21 2010-12-07 Human Genome Sciences, Inc. Albumin fusion proteins

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
PT888385E (en) 1996-03-14 2004-01-30 Genentech Inc UTILIZATIONS OF GDNF AND GDNF RECEPTORS
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
WO2000068376A1 (en) * 1999-05-07 2000-11-16 Genentech, Inc. Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
US6555343B1 (en) 1999-05-07 2003-04-29 Genentech Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6831060B2 (en) 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
JP5022551B2 (en) * 2000-04-21 2012-09-12 アムジエン・インコーポレーテツド Methods and compositions for the prevention and treatment of anemia
HU230874B1 (en) 2000-05-15 2018-11-29 F. Hoffmann-La Roche Ag Liquid pharmaceutical compositions stable at room temperature which comprising a pegylated human erythropoietin protein
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
AU2003251770B9 (en) * 2002-07-01 2009-06-04 H. Lundbeck A/S Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
AU2003246486A1 (en) * 2002-07-19 2004-02-09 Cangene Corporation Pegylated erythropoietic compounds
PL1644363T3 (en) 2003-05-30 2012-07-31 Gemin X Pharmaceuticals Canada Inc Triheterocyclic compounds, compositions, and methods for treating cancer
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US20090029907A1 (en) * 2005-05-24 2009-01-29 Avesthagen Limited Recombinant Method for Production of an Erythropoiesis Stimulating Protein
WO2007070315A2 (en) 2005-12-08 2007-06-21 Amgen Inc. Improved production of glycoproteins using manganese
ES2434494T3 (en) 2005-12-08 2013-12-16 Amgen, Inc. Enhanced host cells and culture methods
EP2498096A1 (en) 2006-07-21 2012-09-12 Amgen Inc. Method of detecting and/or measuring hepcidin in a sample
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
ES2500066T3 (en) 2008-01-25 2014-09-30 Amgen, Inc Ferroportin antibodies and methods of use
MX2010011717A (en) 2008-05-01 2010-11-30 Amgen Inc Anti-hepcidin antibodies and methods of use.
CN101323630B (en) * 2008-07-25 2013-06-05 中国科学院上海有机化学研究所 Transient metal complex compound, synthetic method and use thereof
EP3693014A1 (en) 2008-11-13 2020-08-12 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation bmp-6
WO2011011674A2 (en) 2009-07-24 2011-01-27 Dr. Reddy's Laboratories Ltd. Production of erythropoiesis stimulating protein using metal ions
CA2777226A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
EP2490957B1 (en) 2009-10-23 2016-11-23 Amgen, Inc Vial adapter and system
PL2575935T5 (en) 2010-06-07 2023-12-11 Amgen Inc. Drug delivery device
EP2691065B1 (en) 2011-03-31 2017-03-01 Amgen Inc. Vial adapter and system
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
CA3145238A1 (en) 2011-04-20 2012-10-26 Amgen Inc. Autoinjector apparatus
SI3335747T1 (en) 2011-10-14 2021-08-31 Amgen Inc. Injector and method of assembly
SI3081249T1 (en) 2012-11-21 2021-03-31 Amgen Inc. Drug delivery device
KR102218494B1 (en) 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 Anti-hepcidin antibodies and uses thereof
CA2904725C (en) 2013-03-15 2022-04-12 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
EP3593839A1 (en) 2013-03-15 2020-01-15 Amgen Inc. Drug cassette
CN113559363B (en) 2013-03-22 2023-10-31 美国安进公司 Syringe and method of assembly
MX2016005315A (en) 2013-10-24 2016-08-11 Amgen Inc Drug delivery system with temperature-sensitive control.
KR102458637B1 (en) 2013-10-24 2022-10-24 암겐 인코포레이티드 Injector and method of assembly
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
MX2016014561A (en) 2014-05-07 2017-06-21 Amgen Inc Autoinjector with shock reducing elements.
EP4036924A1 (en) 2014-06-03 2022-08-03 Amgen, Inc Devices and methods for assisting a user of a drug delivery device
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
EP3943135A3 (en) 2014-10-14 2022-06-29 Amgen Inc. Drug injection device with visual and audible indicators
JP2017538512A (en) 2014-12-19 2017-12-28 アムジエン・インコーポレーテツド Drug delivery device including live button or user interface field
EP3233163B1 (en) 2014-12-19 2021-10-13 Amgen Inc. Drug delivery device with proximity sensor
US10682365B2 (en) 2014-12-31 2020-06-16 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
AU2016220141B2 (en) 2015-02-17 2018-07-12 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EP3386573B1 (en) 2015-12-09 2019-10-02 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
US11200298B2 (en) 2016-03-15 2021-12-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018053142A2 (en) * 2016-09-14 2018-03-22 President And Fellows Of Harvard College Methods and compositions for modulating erythropoiesis
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
MX2019009625A (en) 2017-02-17 2019-10-09 Amgen Inc Drug delivery device with sterile fluid flowpath and related method of assembly.
EP3582829A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Insertion mechanism for drug delivery device
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
MX2019010543A (en) 2017-03-07 2019-10-21 Amgen Inc Needle insertion by overpressure.
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for drug delivery device
EP3570871B1 (en) 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
BR112019020053B1 (en) 2017-03-28 2023-10-10 Amgen Inc MACHINE FOR ATTACHING A PLUS ROD TO A SYRINGE ASSEMBLY AND METHOD OF USING SAID MACHINE
AU2018282077B2 (en) 2017-06-08 2023-11-23 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
EP3641857A1 (en) 2017-06-22 2020-04-29 Amgen Inc. Device activation impact/shock reduction
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
EP3651832B1 (en) 2017-07-14 2023-12-13 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
WO2019018169A1 (en) 2017-07-21 2019-01-24 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
JP7242562B2 (en) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド Drug delivery device with container access system and associated method of assembly
MA49677A (en) 2017-07-25 2021-04-21 Amgen Inc DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSOCIATED ASSEMBLY PROCESS
US20200164155A1 (en) 2017-08-09 2020-05-28 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
ES2939292T3 (en) 2017-10-04 2023-04-20 Amgen Inc Flow adapter for drug delivery device
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
EP3703779A1 (en) 2017-11-03 2020-09-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
EP3706830A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Drug delivery device with placement and flow sensing
SG11202002966QA (en) 2017-11-10 2020-05-28 Amgen Inc Plungers for drug delivery devices
MX2020005066A (en) 2017-11-16 2020-08-20 Amgen Inc Autoinjector with stall and end point detection.
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
MX2021000749A (en) 2018-07-24 2021-03-29 Amgen Inc Delivery devices for administering drugs.
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023444A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
US20210228797A1 (en) 2018-07-31 2021-07-29 Amgen Inc. Fluid path assembly for a drug delivery device
WO2020068623A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
EP3856283A1 (en) 2018-09-28 2021-08-04 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
CA3110529A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
EP3860686A1 (en) 2018-10-05 2021-08-11 Amgen Inc. Drug delivery device having dose indicator
JP2022504769A (en) 2018-10-15 2022-01-13 アムジエン・インコーポレーテツド Drug delivery device with damping mechanism
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
US20220031939A1 (en) 2018-11-01 2022-02-03 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
MA54048A (en) 2018-11-01 2022-02-09 Amgen Inc DRUG DELIVERY DEVICES WITH PARTIAL RETRACTION OF DRUG DELIVERY BODY
TWI831847B (en) 2018-11-01 2024-02-11 美商安進公司 Drug delivery devices with partial needle retraction and methods for operating the same
MX2021012557A (en) 2019-04-24 2021-11-12 Amgen Inc Syringe sterilization verification assemblies and methods.
AU2020337250A1 (en) 2019-08-23 2022-03-03 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
BR112023024278A2 (en) 2021-05-21 2024-01-30 Amgen Inc METHOD OF OPTIMIZING A FILLING RECIPE FOR A DRUG CONTAINER
WO2023209074A1 (en) 2022-04-28 2023-11-02 Institut National de la Santé et de la Recherche Médicale Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
WO2024094457A1 (en) 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Method for producing glycoprotein compositions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267678A1 (en) * 1986-09-15 1988-05-18 Genzyme Corporation Recombinant human erythropoietin
WO1991005867A1 (en) * 1989-10-13 1991-05-02 Amgen Inc. Erythropoietin isoforms
WO1995005465A1 (en) * 1993-08-17 1995-02-23 Amgen Inc. Erythropoietin analogs
US5541458A (en) * 1994-11-14 1996-07-30 Hewlett-Packard Company Power supply for timed residual power after turn off
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
WO1999011781A1 (en) * 1997-09-01 1999-03-11 Aventis Pharma Deutschland Gmbh Recombinant human erythropoietin with advantageous glycosylation profile

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19535571A1 (en) * 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Combined pharmaceutical preparations and their use for the treatment of hemodialysis patients

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267678A1 (en) * 1986-09-15 1988-05-18 Genzyme Corporation Recombinant human erythropoietin
WO1991005867A1 (en) * 1989-10-13 1991-05-02 Amgen Inc. Erythropoietin isoforms
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
WO1995005465A1 (en) * 1993-08-17 1995-02-23 Amgen Inc. Erythropoietin analogs
US5541458A (en) * 1994-11-14 1996-07-30 Hewlett-Packard Company Power supply for timed residual power after turn off
WO1999011781A1 (en) * 1997-09-01 1999-03-11 Aventis Pharma Deutschland Gmbh Recombinant human erythropoietin with advantageous glycosylation profile

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EGRIE J C ET AL.: "The role of carbohydrate on the biological activity of erythropoietin", GLYCOCONJUGATE JOURNAL, 15 August 1993 (1993-08-15) - 20 August 1993 (1993-08-20), Abstracts of XIIth International Symposium, pages 263, XP000906829 *
ELLIOTT STEVE ET AL.: "Structural requirements for addition of O-linked carbohydrate to recombinant erythropoietin.", BIOCHEMISTRY, vol. 33, no. 37, 17 September 1994 (1994-09-17), pages 11237 - 11245, XP000906783 *
FIBI M R ET AL: "N- AND O-GLYCOSYLATION MUTEINS OF RECOMBINANT HUMAN ERYTHROPOIETIN SECRETED FROM BHK-21CELLS", BLOOD, vol. 85, no. 5, 1 March 1995 (1995-03-01), pages 1229 - 1236, XP002053700 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7847079B2 (en) 2001-12-21 2010-12-07 Human Genome Sciences, Inc. Albumin fusion proteins
US8071539B2 (en) 2001-12-21 2011-12-06 Human Genome Sciences, Inc. Albumin fusion proteins
US8252739B2 (en) 2001-12-21 2012-08-28 Human Genome Sciences, Inc. Albumin fusion proteins
US8513189B2 (en) 2001-12-21 2013-08-20 Human Genome Sciences, Inc. Albumin fusion proteins
US8993517B2 (en) 2001-12-21 2015-03-31 Human Genome Sciences, Inc. Albumin fusion proteins
US9221896B2 (en) 2001-12-21 2015-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
US9296809B2 (en) 2001-12-21 2016-03-29 Human Genome Sciences, Inc. Albumin fusion proteins

Also Published As

Publication number Publication date
IL142334A (en) 2010-04-29
JP2002528465A (en) 2002-09-03
DE69935345T2 (en) 2007-07-05
JP5558213B2 (en) 2014-07-23
JP2010248207A (en) 2010-11-04
KR20010075661A (en) 2001-08-09
DE69935345D1 (en) 2007-04-12
CN1346369A (en) 2002-04-24
DE69935345T3 (en) 2018-03-01
HK1040944A1 (en) 2002-06-28
ES2283139T5 (en) 2018-03-05
CA2345882C (en) 2011-02-01
EP1813624B1 (en) 2010-08-11
CY1107584T1 (en) 2013-03-13
HUP0103920A3 (en) 2006-04-28
EP1123313B1 (en) 2007-02-28
SI1123313T1 (en) 2007-06-30
HUP0103920A2 (en) 2002-02-28
CY1110801T1 (en) 2015-06-10
ATE477270T1 (en) 2010-08-15
HK1040944B (en) 2007-09-07
EP1813624A1 (en) 2007-08-01
ES2283139T3 (en) 2007-10-16
SI1813624T1 (en) 2010-12-31
AU774989B2 (en) 2004-07-15
PT1813624E (en) 2010-10-27
DK1123313T3 (en) 2007-06-18
ATE355303T1 (en) 2006-03-15
DK1813624T3 (en) 2010-11-22
DE69942680D1 (en) 2010-09-23
AR020848A1 (en) 2002-05-29
EP1123313B2 (en) 2018-01-10
JP4809977B2 (en) 2011-11-09
PT1123313E (en) 2007-04-30
IL196645A (en) 2012-08-30
HU228492B1 (en) 2013-03-28
CN101703760A (en) 2010-05-12
CN1346369B (en) 2011-09-28
AU1124100A (en) 2000-05-15
EP1123313A2 (en) 2001-08-16
TWI234583B (en) 2005-06-21
WO2000024893A2 (en) 2000-05-04
CA2345882A1 (en) 2000-05-04
ES2347884T3 (en) 2010-11-22

Similar Documents

Publication Publication Date Title
WO2000024893A3 (en) Methods and compositions for the prevention and treatment of anemia
WO2001081405A3 (en) Methods and compositions for the prevention and treatment of anemia
ZA94737B (en) Pulmonary administration of erythropoietin
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
UA56989C2 (en) PHYSIOLOGICALLY ACTIVE PEG-CONJUGATE OF a-INTERFERON, A METHOD FOR PREPARING THE SAME, A PHARMACEUTICAL COMPOSITION BASED THEREON AND A METHOD FOR TREATMENT OR PROPHYLAXIS OF IMMUNOMODULAR DISEASES
AU6586896A (en) Fatty acid treatment
EP0951910A3 (en) Method for administering monomeric insulin analogs
CA2093806A1 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
HUT50443A (en) Process for producing pharmaceutical composition suitable for treating diabetes mellitus
WO2000043034A3 (en) Monodisperse hexameric acylated insulin analog formulations
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
WO2000040273A3 (en) Treatment of viral diseases using an interferon omega expressing polynucleotide
AU7128296A (en) Pharmaceutical combination preparations containing erythropoietin and iron preparations
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2004004664A3 (en) Methods for treating or preventing ischemic injury
WO1999064598A3 (en) Novel insulin analogs with enhanced zinc binding
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
EP0821969A3 (en) Medicinal Composition comprising TCF-II
WO2003032909A3 (en) Methods of treating skin with diphosphonate derivatives
CA2211413A1 (en) Human dnase i variants
WO1999021538A3 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
HUP0203309A3 (en) Therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics for treatment or prevention of phychotic disorders and pharmaceutical compositions containing them
EP1712231A3 (en) Method for improving the pharmacokinetics of tipranavir
WO2000011137A8 (en) Acid labile cationic amphiphiles

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99814697.8

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 11241

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 11241/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 142334

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2345882

Country of ref document: CA

Ref document number: 2345882

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/003867

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 578445

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017005047

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1999955046

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017005047

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999955046

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 11241/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999955046

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 221108

Country of ref document: IL